OBJECTIVE: Medically refractory angina remains a significant health concern despite major advances in revascularization techniques and emerging medical therapies. We aimed to determine the safety and efficacy of extracorporeal shockwave myocardial therapy (ESMT) in managing angina pectoris. METHODS: A single-arm multicenter prospective study was designed aiming to determine the safety and efficacy of ESMT. Patients of functional Canadian Cardiovascular Society class II-IV, despite stable and optimal medical management, with documented myocardial segments with reversible ischemia and/or hibernation on the basis of echocardiography/single-photon emission computerized tomography (SPECT) were enrolled from 2010 to 2012. A total of 111 patients were enrolled, 33 from Indonesia, 21 from Malaysia, and 57 from Philippines. Patients underwent nine cycles of ESMT over 9 weeks. Patients were followed up for 3-6 months after ESMT treatment. During follow-up, patients were subjected to clinical evaluation, the Seattle Angina Questionnaire, assessment of nitrate intake, the 6-min walk test, echocardiography, and SPECT. RESULTS: The mean age of the population was 62.9±10.9 years. The summed difference score on pharmacologically induced stress SPECT improved from 9.53±17.87 at baseline to 7.77±11.83 at follow-up (P=0.0086). Improvement in the total Seattle Angina Questionnaire score was seen in 83% of patients (P<0.0001). Sublingual nitroglycerin use significantly decreased (1.14±1.01 tablets per week at baseline to 0.52±0.68 tablets per week at follow-up; P=0.0215). There were no changes in left ventricular function on echocardiography (0.33±9.97, P=0.93). The Canadian Cardiovascular Society score improved in 74.1% of patients. CONCLUSION: This multicenter prospective trial demonstrated that ESMT is both a safe and an efficacious means of managing medically refractory angina.
OBJECTIVE: Medically refractory angina remains a significant health concern despite major advances in revascularization techniques and emerging medical therapies. We aimed to determine the safety and efficacy of extracorporeal shockwave myocardial therapy (ESMT) in managing angina pectoris. METHODS: A single-arm multicenter prospective study was designed aiming to determine the safety and efficacy of ESMT. Patients of functional Canadian Cardiovascular Society class II-IV, despite stable and optimal medical management, with documented myocardial segments with reversible ischemia and/or hibernation on the basis of echocardiography/single-photon emission computerized tomography (SPECT) were enrolled from 2010 to 2012. A total of 111 patients were enrolled, 33 from Indonesia, 21 from Malaysia, and 57 from Philippines. Patients underwent nine cycles of ESMT over 9 weeks. Patients were followed up for 3-6 months after ESMT treatment. During follow-up, patients were subjected to clinical evaluation, the Seattle Angina Questionnaire, assessment of nitrate intake, the 6-min walk test, echocardiography, and SPECT. RESULTS: The mean age of the population was 62.9±10.9 years. The summed difference score on pharmacologically induced stress SPECT improved from 9.53±17.87 at baseline to 7.77±11.83 at follow-up (P=0.0086). Improvement in the total Seattle Angina Questionnaire score was seen in 83% of patients (P<0.0001). Sublingual nitroglycerin use significantly decreased (1.14±1.01 tablets per week at baseline to 0.52±0.68 tablets per week at follow-up; P=0.0215). There were no changes in left ventricular function on echocardiography (0.33±9.97, P=0.93). The Canadian Cardiovascular Society score improved in 74.1% of patients. CONCLUSION: This multicenter prospective trial demonstrated that ESMT is both a safe and an efficacious means of managing medically refractory angina.
Authors: Ahmed A Khattab; Broder Brodersen; Daniela Schuermann-Kuchenbrandt; Hans Beurich; Ralph Tölg; Volker Geist; Torsten Schäfer; Gert Richardt Journal: Int J Cardiol Date: 2006-11-09 Impact factor: 4.164
Authors: Douglas W Losordo; Timothy D Henry; Charles Davidson; Joon Sup Lee; Marco A Costa; Theodore Bass; Farrell Mendelsohn; F David Fortuin; Carl J Pepine; Jay H Traverse; David Amrani; Bruce M Ewenstein; Norbert Riedel; Kenneth Story; Kerry Barker; Thomas J Povsic; Robert A Harrington; Richard A Schatz Journal: Circ Res Date: 2011-07-07 Impact factor: 17.367
Authors: J M Isner; A Pieczek; R Schainfeld; R Blair; L Haley; T Asahara; K Rosenfield; S Razvi; K Walsh; J F Symes Journal: Lancet Date: 1996-08-10 Impact factor: 79.321
Authors: C Mannheimer; T Eliasson; L E Augustinsson; C Blomstrand; H Emanuelsson; S Larsson; H Norrsell; A Hjalmarsson Journal: Circulation Date: 1998-03-31 Impact factor: 29.690
Authors: Birgit Assmus; Dirk H Walter; Florian H Seeger; David M Leistner; Julia Steiner; Ina Ziegler; Andreas Lutz; Walaa Khaled; Jens Klotsche; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: JAMA Date: 2013-04-17 Impact factor: 56.272
Authors: Christian Prinz; Oliver Lindner; Thomas Bitter; Detlef Hering; Wolfgang Burchert; Dieter Horstkotte; Lothar Faber Journal: Case Rep Med Date: 2009-08-20
Authors: Xin Zhang; James D Krier; Carolina Amador Carrascal; James F Greenleaf; Behzad Ebrahimi; Ahmad F Hedayat; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: J Am Soc Nephrol Date: 2016-06-13 Impact factor: 10.121
Authors: Greta Burneikaitė; Evgeny Shkolnik; Jelena Čelutkienė; Gitana Zuozienė; Irena Butkuvienė; Birutė Petrauskienė; Pranas Šerpytis; Aleksandras Laucevičius; Amir Lerman Journal: Cardiovasc Ultrasound Date: 2017-04-12 Impact factor: 2.062
Authors: Jelena Čelutkienė; Greta Burneikaitė; Evgeny Shkolnik; Gabrielius Jakutis; Donatas Vajauskas; Kamilė Čerlinskaitė; Gitana Zuozienė; Birutė Petrauskienė; Roma Puronaitė; Renata Komiagienė; Irena Butkuvienė; Rima Steponėnienė; Jonas Misiūra; Aleksandras Laucevičius Journal: Cardiovasc Ultrasound Date: 2019-07-04 Impact factor: 2.062